Product Description
Mechanisms of Action: Immunosuppressive Immuno
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioMS Technology Corp.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis
Phase 2: Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-001947-70 | P2 |
Completed |
Multiple Sclerosis |
2009-09-25 |
|
MINDSET01 | P3 |
Completed |
Multiple Sclerosis, Relapsing-Remitting |
2009-09-01 |
|
MAESTRO-02 | P3 |
Terminated |
Multiple Sclerosis, Chronic Progressive |
2009-09-01 |
|
MAESTRO-03 | P3 |
Terminated |
Multiple Sclerosis, Chronic Progressive |
2009-07-01 |